Comparative Efficacy of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Treatment of Macular Oedema Secondary to Central Retinal Vein Occlusion

Abstract

Macular edema due to retinal vein occlusion hold the second rank of the most common type of retinal vascular diseases after diabetic retinopathy. Progressively blurry vision in patients with central retinal vein occlusion mainly results from macular edema ending with significant vision loss. Most people with macular edema due to CRVO will need treatment and the number of options has increased in recent years. Apart from panretinal photocoagulation for CRVO treatment, intravitreal corticosteroids have been used to treat macular edema secondary to CRVO but they are likely to increase the risk of cataract progression and intraocular pressure elevation.Recently, anti-vascular endothelial growth factor (VEGF) therapy has become the treatment of choice for this ocular disorder. Ranibizumab and aflibercept have been licensed for treating various retinal diseases, while bevacizumab has been used off-label. The current study was performed to review efficacy& safety of intravitreal aflibercept, ranibizumab and bevacizumab for the treatment of macular edema Secondary to central retinal vein occlusion.